There are roughly 300 million surgeries performed globally every year. The overwhelming majority happen in open operating theatres. Every one of those procedures is driven by decisions, micro-decisions, pattern recognitions, judgment calls accumulated over years of training made by a skilled human being.

None of it is captured. None of it is learned from at scale.

That is the problem Nuevata exists to solve. And last week, the Polsky Center for Entrepreneurship and Innovation at the University of Chicago agreed selecting us as one of 20 startups in the inaugural cohort of the India Deep Tech Accelerator.

What the Polsky Center is, and why this selection matters

The University of Chicago is not a casual brand 101 Nobel Laureates, 18,000 students, 200,000+ alumni. The Polsky Center is its dedicated engine for translating deep research into globally competitive companies. Harper Court Ventures, its affiliated deep tech fund, operates at $25M. The India Deep Tech Accelerator is Polsky's newest program, built in partnership with the India Deep Tech Alliance and IIT ecosystem partners, with one explicit mandate: close the gap between India's technical invention and global commercialization.

Associate Director Rahul Singal put the program's core insight plainly at kickoff: "One of the biggest gaps we see isn't in technical ability it's in how India's deep tech founders position, communicate, and fundraise at a global level."

What the next 10 weeks unlock

The program culminates in two events: India Demo Day on July 9th with 12-15 active investors expected and a US showcase for the companies that advance further. Beyond the showcases: direct access to Polsky's commercialization faculty, structured mentorship on positioning and fundraising, and connectivity to an investor network that has spent decades backing science-first companies.

Where we stand

Iris, our lightweight wearable capture system, and our AI analytics layer, are in active development. Our existing network of 500+ surgeons built over six years through LUCID Implants gives us clinical access that most surgical AI companies spend years trying to construct from scratch. Our CMO, Dr. Hema Anukula, is a practicing oral cancer surgeon who operates in the environment we're building for.

We are raising ₹5 Crore seed to complete the prototypes, initiate structured clinical pilots, and begin the data flywheel that makes Nuevata genuinely defensible at scale.

If that thesis interests you → contact@nuevata.com